US Bancorp
CGEM icon

US Bancorp’s Cullinan Oncology CGEM Stock Holding History

US Bancorp’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.41K Buy
517
+15
+3% +$223 ﹤0.01% 3464
2026
Q1 		$7.13K Buy
502
+19
+4% +$244 ﹤0.01% 3471
2025
Q4 		$5K Buy
+483
New +$4.36K ﹤0.01% 3531
2025
Q3 		– Sell
-295
Closed -$2.22K – 4057
2025
Q2 		$2.22K Sell
295
-1,262
-81% -$10.1K ﹤0.01% 3852
2025
Q1 		$11.8K Buy
1,557
+1,344
+631% +$12.9K ﹤0.01% 3380
2024
Q4 		$2.6K Buy
213
+96
+82% +$1.38K ﹤0.01% 3806
2024
Q3 		$1.96K Buy
117
+12
+11% +$213 ﹤0.01% 3790
2024
Q2 		$1.83K Sell
105
-323
-75% -$6.88K ﹤0.01% 3734
2024
Q1 		$7.29K Sell
428
-76
-15% -$1.17K ﹤0.01% 3427
2023
Q4 		$5.14K Buy
+504
New +$4.46K ﹤0.01% 3521
2023
Q2 		– Sell
-1,084
Closed -$11.1K – 4009
2023
Q1 		$11.1K Buy
1,084
+517
+91% +$5.7K ﹤0.01% 3242
2022
Q4 		$5.98K Sell
567
-110
-16% -$1.34K ﹤0.01% 3453
2022
Q3 		$9K Buy
677
+186
+38% +$2.51K ﹤0.01% 3390
2022
Q2 		$6K Sell
491
-1,267
-72% -$14.4K ﹤0.01% 3511
2022
Q1 		$18K Buy
1,758
+308
+21% +$4.16K ﹤0.01% 3127
2021
Q4 		$22K Buy
1,450
+1,440
+14,400% +$28.7K ﹤0.01% 3060
2021
Q3 		$0 Buy
+10
New +$267 ﹤0.01% 4087

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

US Bancorp's CGEM Position: Q2 2026 in Review

US Bancorp increased its Cullinan Oncology (CGEM) stake by 3% in Q2 2026, buying an estimated $223 and bringing the position to 517 shares worth $9.41K. The position accounts for ﹤0.01% of the portfolio, ranked #3464.

US Bancorp first reported a position in CGEM in Q3 2021 and has held it in 17 quarters since. The position peaked at $22K in Q4 2021. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • US Bancorp held 517 shares of Cullinan Oncology worth $9.41K as of Q2 2026.
  • US Bancorp bought 15 Cullinan Oncology shares in Q2 2026, an estimated $223.
  • Cullinan Oncology made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3464 holding.
  • US Bancorp first reported a position in Cullinan Oncology in Q3 2021 and has held it in 17 quarters since.
  • US Bancorp's Cullinan Oncology position peaked at $22K in Q4 2021.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.